

For support from hospital to home, Enroll in HemAssist™ Patient Support for CABLIVI* today

Cablivi[®]
caplacizumab-yhdp
Injection 11 mg

SIGNING UP FOR HEMASSIST FOR CABLIVI PROVIDES GUIDANCE AND SUPPORT THROUGHOUT YOUR JOURNEY, FROM HOSPITAL TO HOME

A dedicated team will work together seamlessly to help manage your aTTP/iTTP care:



FINANCIAL ASSISTANCE

Case Managers (your main point of contact) can help you understand the financial support available to you based on your insurance status. CABLIVI will be provided at no cost to eligible, underinsured, or uninsured patients.†



SPECIALTY PHARMACY SERVICES

Case Managers can assist you with managing shipment of your CABLIVI therapy to your home if your doctor prescribes CABLIVI through a specialty pharmacy.



PRODUCT ADMINISTRATION TRAINING

Clinical Educators‡ (CEs) can provide one-on-one supplemental product administration education and resources to help ensure confidence in CABLIVI reconstitution and self-administration.



ONGOING EDUCATION

Clinical Educators‡ (CEs) are committed to educating people living with aTTP/iTTP about topics such as disease education, how you can be an advocate for yourself in managing your condition, and having empowering conversations with your healthcare team.



Your team at HemAssist for CABLIVI is ready to help

Get started today by calling **1-833-723-5463** to enroll.

Questions about the program?

Call **1-833-723-5463** Monday - Friday 8 AM to 7 PM ET.

Learn more about available resources at CABLIVI.com/aTTP
or refer to the next page for more details

INDICATION AND IMPORTANT SAFETY INFORMATION

What is CABLIVI?

CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

Who should not take CABLIVI?

Do not take CABLIVI if you've had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.

aTTP=acquired thrombotic thrombocytopenic purpura; iTTP=immune-mediated thrombotic thrombocytopenic purpura.

*Sanofi reserves the right to modify or terminate these programs at any time without notice.

†Approval is not guaranteed. Sanofi reserves the right to modify or discontinue the programs at any time. Terms and conditions apply.

‡Clinical Educators are Sanofi employees and do not provide medical advice. Patients should always consult their doctors with any questions or concerns regarding their medical condition or health care needs.

After enrolling in HemAssist for CABLIVI, view additional helpful resources

YOU CAN ACCESS THE FOLLOWING AT [CABLIVI.COM/aTTP](https://cablivi.com/aTTP):

- **[CABLIVI Patient Brochure](#)**: Learn more about aTTP/iTTP and how CABLIVI works
- **[CABLIVI Administration Training Guide](#)**: Step-by-step instructions to help with the administration of CABLIVI
- **[CABLIVI Doctor Discussion Guide](#)**: Suggested questions to ask your doctor about treatment with CABLIVI
- **[The Language of aTTP/iTTP Guide](#)**: A list of common terms and definitions to help you discuss aTTP/iTTP with your healthcare team and family



Learn how to take CABLIVI at home

Watch the CABLIVI Administration Video by visiting [How to take CABLIVI | CABLIVI \(caplacizumab-yhdp\)](#)

Questions about the program?

Call **1-833-723-5463** Monday - Friday 8 AM to 7 PM ET.

IMPORTANT SAFETY INFORMATION (cont'd)

What should I tell my healthcare team before starting CABLIVI?

Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take, including medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.

Talk to your doctor before scheduling any surgery, medical or dental procedure.

What are the possible side effects of CABLIVI?

CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. In the post-marketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI. Contact your doctor immediately if symptoms of excessive bruising, excessive bleeding, or major bleeding occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.

You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.

CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.

The most common side effects include nosebleed, headache and bleeding gums.

Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.

Please see accompanying full [Prescribing Information](#).